(Q43762369)

English

Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Ohkawa K

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Hiramatsu N

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mochizuki K

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mita E

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Iio S

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Yoshihara H

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Kato M

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Masuzawa M

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Kasahara A

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sasaki Y

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Hori M

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Hayashi N

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1009-1014

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

The Fas death factor

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Lethal effect of the anti-Fas antibody in mice

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Role of Fas ligand in apoptosis induced by hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02539.X

21 January 2018

Identifiers

10.1046/J.1440-1746.2001.02539.X

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43762369&oldid=2103119486"